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Background: Painful diabetic neuropathy (PDN) is a serious complication of diabetes mellitus that affects a large
number of patients in many countries. The molecular mechanisms underlying the exaggerated nociception in PDN
have not been established. Recently, duloxetine (DLX), a serotonin and noradrenaline re-uptake inhibitor, has been
recommended as one of the first-line treatments of PDN in the United States Food and Drug Administration, the
European Medicines Agency and the Japanese Guideline for the Pharmacologic Management of Neuropathic pain.
Because selective serotonin re-uptake inhibitors show limited analgesic effects in PDN, we examined whether the
potent analgesic effect of DLX contributes toward improving the pathologically aberrant noradrenaline homeostasis
in diabetic models.
Results: In streptozotocin (STZ) (50 mg/kg, i.v.)-induced diabetic rats that exhibited robust mechanical allodynia and
thermal hyperalgesia, DLX (10 mg/kg, i.p.) significantly and markedly increased the nociceptive threshold. The
analgesic effect of DLX was nullified by the prior administration of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine
(DSP-4) (50 mg/kg, i.p.), which drastically eliminated dopamine-beta-hydroxylase- and norepinephrine transporter-
immunopositive fibers in the lumbar spinal dorsal horn and significantly reduced the noradrenaline content in the
lumbar spinal cord. The treatment with DSP-4 alone markedly lowered the nociceptive threshold in vehicle-treated
non-diabetic rats; however, this pro-nociceptive effect was occluded in STZ-treated diabetic rats. Furthermore,
STZ-treated rats exhibited a higher amount of dopamine-beta-hydroxylase- and norepinephrine transporter-
immunopositive fibers in the dorsal horn and noradrenaline content in the spinal cord compared to vehicle-treated rats.
Conclusions: Impaired noradrenaline-mediated regulation of the spinal nociceptive network might underlie exaggerated
nociception in PDN. DLX might exert its analgesic effect by selective enhancement of noradrenergic signals, thus
counteracting this situation.
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Diabetic neuropathy is one of the most frequent compli-
cations of diabetes mellitus (DM) [1]. Of the major
symptoms associated with diabetic neuropathy, exagge-
rated pain crucially impairs the physical and mental com-
ponents of quality of life in a large number of patients
with types 1 and 2 DM [2,3]. This complication of DM,* Correspondence: fusao@jikei.ac.jp
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stated.often called painful diabetic neuropathy (PDN), is char-
acterized by allodynia, which is an aberrant painful sen-
sation to normally innocuous stimuli, and hyperalgesia,
which is an increased sensitivity to painful stimuli [4,5].
Such exaggerated nociception is also reproduced in animal
models of DM, such as the type 1 DM model induced
with streptozotocin (STZ), an agent that selectively des-
troys pancreatic β cells after being taken up through glu-
cose transporter 2 [6]. The animals treated with STZ
show, in addition to robust hyperglycemia and hypoinsuli-
nemia, severe chronic pain characterized with decreased
mechanical and thermal pain threshold [6]. Despite theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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mechanisms underlying the exaggerated nociception in
diabetic patients and animal models have not been estab-
lished [7]. Identifying these mechanisms would facilitate
the development of novel and more effective medical in-
terventions for PDN.
Recently, duloxetine (DLX), an antidepressant with a
serotonin (5-HT) and noradrenaline (NA) re-uptake in-
hibitor (SNRI), has been shown to be highly effective in
relieving pain in diabetic patients [8-10] and in STZ-
treated animal models [11-13]. This pain relief effect is
not unique to DLX, and it is possessed by other SNRIs,
which also improve the exaggerated pain in diabetic pa-
tients [14] and animal models [15,16]. SNRIs, including
DLX, are recommended to be one of the first-line treat-
ments for patients with PDN [5,17]. Though there is a
high incidence of PDN-depression complication, it is un-
likely that this pain-relieving effect of DLX is a simple
consequence of the amelioration of depression because
DLX relieves neuropathic pain without significantly im-
proving depression in patients with such complication
[18,19]. These lines of evidence support the notion that
not only the peripheral nerve damage but also a failure
in NA/5-HT regulation would underlie the pathogenesis
of PDN and this would be the target of DLX. Addition-
ally, because of the absence of a significant effect of se-
lective 5-HT re-uptake inhibitors (SSRIs), which is
another group of widely used antidepressants in human
patients [20], it is suggested that a modulation of NA
homeostasis by DLX underlies its pain relief in DM
patients.
Indeed, aberrant NA homeostasis is reported in another
form of chronic pain model with peripheral nerve injury
[21]. It is possible that hyperglycemia-induced neuropathy
[22] and spinal cord inflammation [6], as observed also in
the nerve-injury models [23], gave rise to aberrant NA
homeostasis also in the PDN models. Interestingly, a re-
cent study suggested that insulin signal is involved in the
regulation of NA homeostasis [24]. This finding is of high
importance because low-dose insulin itself has potent
analgesic effect [25] as well as ameliorative effects on the
neuropathy [22]. A possible hypothesis would be that,
in the PDN animals, aberrant NA homeostasis resulting
from both of hyperglycemia-induced neuropathy and
hypoinsulinemia-induced modulation of NA homeostasis
would exacerbate the hyperalgesic behaviors. If this is the
case, it is expected that rectification of NA homeostasis
would potently relieve pain in PDN animals in a manner
dependent on recuperation of NA-mediated regulation of
spinal nociception.
In the present study, we demonstrate that an improve-
ment in pathologically aberrant NA homeostasis under-
lies the potent analgesic effect of DLX in diabetic
models. To address this issue, we evaluated the effects ofDLX on nocifensive behaviors and the expression of
molecules for NA homeostasis in the spinal cord in STZ
models using histochemical and biochemical approaches;
we also examined the effects of the pharmacological de-
letion of noradrenergic fibers. The results strongly sug-
gest that the mechanisms that regulate the spinal NA
levels, presumably arising from the descending pain
regulatory system [26,27], become dysfunctional in the
PDN models and that DLX exerts its analgesic effect by
improving this dysfunction.
Results
Blood glucose levels and body weights of the
experimental groups
Rats treated with STZ (50 mg/kg, i.v.) consistently
showed significantly higher blood glucose levels (range,
431–600 mg/dl; n = 20) compared to the rats treated
with vehicle (range, 123–172 mg/dl; n = 20) at 1 week
after STZ injection (Figure 1A, left). Such hyperglycemia
was observed in all of the rats at 6 weeks after STZ in-
jection (Figure 1A, right). In this series, 50% of the rats
received N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine
(DSP-4) (50 mg/kg, i.p.), a medication that selectively
degenerates noradrenergic fibers [28], at 4 weeks after
STZ injection. This medication did not significantly affect
the blood glucose levels in both STZ- and vehicle-
treated groups (Figure 1A, right). The DLX injection
(10 mg/kg, i.p.) at 2 hours before blood sampling at
6 weeks after STZ injection did not significantly affect
the blood glucose levels (Figure 1A, right). The body
weights of STZ-treated rats were significantly lower
than those of vehicle-treated rats during 6 weeks of ob-
servation (Figure 1B, circles). DSP-4 treatment at the
4th week after STZ injection significantly decreased the
body weights at the 5th and 6th weeks in vehicle-
treated rats (Figure 1B, filled squares) [29] but not in
STZ-treated rats (Figure 1B, filled circles). These obser-
vations indicate that all of the rats that received STZ
became diabetic, in accordance with previous reports
[30,31], and this effect did not occur with the adminis-
tration of DSP-4 and DLX.
STZ induced thermal hyperalgesia and mechanical
allodynia, which was occluded by pre-treatment DSP-4
In agreement with previous reports [6,31], the diabetic rats
showed increased nocifensive behaviors. The paw with-
drawal latency to thermal stimulation (Figure 2A, circles)
and the paw withdrawal threshold to mechanical stimula-
tion (Figure 2B, circles) were significantly decreased after
the second week of STZ injection and lasted at least for
6 weeks after injection. DSP-4 treatment at the 4th week
decreased the latency to thermal stimulation (Figure 2A,
filled squares) and threshold to mechanical stimulation
(Figure 2B, filled squares) in vehicle-treated animals, similar
Figure 1 Metabolic profiles of the experimental groups. (A) Blood glucose levels for the rats treated with STZ and vehicle. Each marker
represents the value measured in each rat belonging to different groups (shown in the inset). The horizontal bars indicate the mean of blood glucose
levels for each group. Left, values measured at 1 week (wk) after STZ injection; ***P < 0.001 (Mann–Whitney U-test) between STZ-treated (open circles)
and vehicle-treated (open squares) groups. Each experimental group was composed of 20 rats. Right, values measured at 6 weeks (wks) after STZ
injection; ***P < 0.001 (Mann–Whitney U-test) between STZ-treated (circles and triangles) and vehicle-treated (squares and diamonds) groups; NS, not
significantly different (Kruskal-Wallis one-way ANOVA) between saline + DW, saline + DLX, DSP-4 + DW and DSP-4 + DLX groups in the rats treated with
STZ and vehicle. Each experimental group was composed of 5 rats. (B) Time course of body weights of the rats treated with STZ and vehicle. At week
0, the rats received i.v. injection of STZ (n = 20 rats) or vehicle (n = 20) (arrow on the left-bottom). At 4 weeks after STZ injection, the rats received i.p.
injection of DSP-4 (n = 10 rats) or saline (n = 10) (black arrowhead). The mean and SEM (vertical bars) values of 10 rats for each experimental group
are shown. **P < 0.01; ***P < 0.001 (ANOVA repeated-measures) between STZ-treated (circles) and vehicle-treated (squares) groups; ###P < 0.001
(ANOVA repeated-measures) between vehicle + saline (open squares) and vehicle + DSP-4 (filled squares) groups; NS, not significantly different
(ANOVA repeated-measures) between STZ + saline (open circles) and STZ + DSP-4 (filled circles) groups.
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tegrity of the noradrenergic system leads to exaggerated
nocifensive behaviors. Surprisingly, this pro-nociceptive ef-
fect of DSP-4 was not observed in STZ-treated animals
(Figure 2A and B, filled circles), which indicated that the
pro-nociceptive effect of DSP-4 was occluded in STZ-
treated diabetic rats.
Effects of DLX on STZ-induced hyperalgesia/allodynia in
DSP-4 pretreated animals
DLX, one of the first-choice medications for PDN [5,17], is
an inhibitor of 5-HT and NA transporters. The decreased
latency to thermal stimulation (Figure 3Aa; compare“Saline” and “DSP-4”) and the lowered threshold for mech-
anical stimulation (Figure 3Ba) in STZ-treated animals
were significantly increased by a single injection of DLX
(10 mg/kg, ip), supporting its pain relieving effect in the
STZ models of PDN [11-13]. DLX exerted no significant
changes in vehicle-treated rats (Figure 3Ab and Bb, “Sa-
line”). In contrast, in the STZ-treated rats that received
DSP-4 injection, DLX exerted no significant effect on both
the thermal and the mechanical thresholds (Figure 3Aa
and Ba, “DSP-4”). This absence of a DLX effect in DSP-4-
treated rats was also similarly observed in vehicle-treated
rats (Figure 3Ab and Bb, “DSP-4”). In this series of study,
we have measured the nocifensive behaviors before and
Figure 2 Effects of STZ and DSP-4 on thermal and mechanical nociception. Time course of thermal hyperalgesia (A) and mechanical
allodynia (B) in the rats treated with STZ and vehicle. At week 0, rats received an i.v. injection of STZ (n = 20 rats) or vehicle (n = 20) (arrow on the
left-bottom). At 4 weeks after STZ injection, the rats received an i.p. injection of DSP-4 (n = 10 rats) or saline (n = 10) (black arrowhead). The mean
and SEM (vertical bars) values of 10 rats for each experimental group are shown. **P < 0.01; ***P < 0.001 (ANOVA repeated-measures) between
STZ-treated (circles) and vehicle-treated (squares) groups; ###P < 0.001 (ANOVA repeated-measures) between vehicle + saline (open squares)
and vehicle + DSP-4 (filled squares) groups; NS, not significantly different (ANOVA repeated-measures) between STZ + saline (open circles) and
STZ + DSP-4 (filled circles) groups.
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evaluate how DLX improved nociception in individual
rats by normalizing the latency (thermal) and threshold
(mechanical) after DLX injection by the values mea-
sured before DLX injection (Figure 3Ac and Bc). This
allowed direct comparison of the efficacy of DLX between
in the absence and presence of DSP-4-treatment. The nor-
malized effects of DLX were almost 1.0 (i.e., almost no ef-
fect) in STZ-treated rats that received DSP-4 and in
vehicle-treated rats with or without DSP-4 (Figure 3Ac
and Bc). In contrast, the effects of DLX on both the ther-
mal and the mechanical nocifensive behaviors weresignificantly greater in STZ-treated rats without DSP-4
injection than in the other groups.
Although to a smaller degree compared to NA fibers,
DSP-4 can be uptaken by 5-HT transporters and degen-
erate serotoninergic fiber terminals [34]. This transport
through 5-HT transporters could be prevented by inhi-
biting 5-HT transporters during the exposure to DSP-4
[28]. To examine whether serotoninergic fiber degener-
ation is involved in the mechanism of DSP-4 reducing
the analgesic effect of DLX, we injected DSP-4 in the
presence and the absence of fluoxetine (10 mg/kg, i.p.), a
selective 5-HT re-uptake inhibitor, and compared the
Figure 3 Effects of DSP-4 on analgesic effects of DLX in STZ-treated rats. Effects of DLX treatment on thermal hyperalgesia (A) and
mechanical allodynia (B) in the rats treated with STZ (a) and vehicle (b) at 6 weeks after STZ injection. The control rats received equal volumes
of distilled water (DW) instead of DLX. Thermal hyperalgesia was assessed at 60 min before (pre-DLX or DW, white columns) and 60 min after
injection of DLX (post-DLX, dark gray columns) or DW (post-DW, light gray columns). Mechanical allodynia was assessed at 30 min before
(pre-DLX or DW) and 90 min after injection of DLX (post-DLX) or DW (post-DW). Circles represent the values at pre-DLX and post-DLX (or DW)
obtained from each rat. Bars indicate the mean values at pre-DLX and post-DLX (or DW). Each experimental group was composed of 5 rats. The
differences in the values of pre-DLX and post-DLX were compared by Wilcoxon signed-rank test. (c) Change in paw withdrawal latency (A) and
threshold (B) by DLX in the rats treated with STZ and vehicle. Change in paw withdrawal latency and threshold by DLX (y-axis for Ac and Bc) was
calculated as the value of post-DLX divided by the value of pre-DLX. The mean ± SEM values of 5 rats for each experimental group are shown.
The differences in the values were compared using the Mann–Whitney U-test.
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line was administered 30 min before the DSP-4 injection
[28]. Regardless of the co-administration of fluoxetine
with DSP-4, DLX failed to increase the nociceptive
thresholds in STZ-treated rats that received DSP-4
(change in paw withdrawal latency by DLX (post-DLX/
pre-DLX): DSP-4 with fluoxetine, 1.01 ± 0.03, n = 5; with-
out fluoxetine, 0.99 ± 0.02, n = 5; P = 0.84; change in paw
withdrawal threshold by DLX (post-DLX/pre-DLX): DSP-4
with fluoxetine, 1.12 ± 0.06, n = 5; without fluoxetine, 1.11 ±0.21, n = 5; P = 0.75) (data not shown in the figure). These
results indicate that the major portion of the analgesic ef-
fects of DLX in STZ-treated diabetic rats depends on the
integrity of spinal noradrenergic systems.
Effects of STZ and DSP-4 on DBH-immunoreactive fibers
in the lumbar spinal dorsal horn
We therefore analyzed the status of the spinal noradrener-
gic system in STZ-treated diabetic rats using histochem-
ical and biochemical approaches. Because the nocifensive
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mechanical threshold) primarily reflect the nociceptor-
activated spinal reflex at the level of the lumbar spinal
cord, we first evaluated the expression of dopamine-
beta-hydroxylase (DBH) protein, an enzyme involved
in the conversion of dopamine to NA, using immuno-
histochemistry analysis of the lumbar spinal dorsal
horn of rats treated with STZ and DSP-4. In the dorsalFigure 4 Effects of STZ and DSP-4 on DBH-immunoreactive fibers in L4-5
fibers in L4-5 dorsal horn in (A) vehicle + saline, (C) STZ + saline, (E) vehicle + D
(B), (D), (F) and (H) are higher magnification of boxed area in (A), (C), (E) and
(G) and the scale bar in (B) is 12.5 μm and applies to (D), (F) and (H). (I) Quan
after STZ injection. Ratio of DBH-immunoreactive pixels to the total pixel numb
horn samples were used for evaluating average ratio values in each rat. The m
*P < 0.05 (Mann–Whitney U-test) between vehicle (Veh) and STZ groups in salin
and DSP-4-treated groups in both STZ and Veh groups; NS, not significantly diffhorn of L4-5 spinal cord of the rats treated with ve-
hicle, DBH-immunoreactive fibers were distributed
throughout the dorsal laminae (Figure 4A-B). This fea-
ture was also observed in the dorsal horn of rats
treated with STZ; however, the density of the DBH-
positive fibers was higher in the STZ-treated group
(Figure 4C-D). The ratio of the DBH-immunopositive
pixels to the total number of gray matter pixels asdorsal horn. Representative photomicrographs of DBH-immunoreactive
SP-4 and (G) STZ + DSP-4 rats at 6 weeks after STZ injection. Panels
(G), respectively. The scale bar in (A) is 50 μm and applies to (C), (E) and
tification of DBH-immunoreactive fibers in L4-5 dorsal horn at 6 weeks
er in the dorsal horn gray matter (see Methods). Four to eleven dorsal
ean ± SEM values of 4 rats for each experimental group are shown.
e-treated animals; #P < 0.05 (Mann–Whitney U-test) between saline-treated
erent.
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lumbar sections was significantly larger in the STZ-
treated group (Figure 4C-D, I) than in the vehicle-
treated rats (Figure 4A-B, I). DSP-4 nearly abolished
DBH-immunopositive fibers both in the STZ- and
vehicle-treated groups (Figure 4E-H, I), which suggested
that DBH-positive fibers were indeed the target of DSP-4.
These data suggest that in the STZ-treated group, the pro-
duction of NA would be increased in the lumbar spinal
dorsal horn.Figure 5 Effects of STZ and DSP-4 on NET-immunoreactivity in L4-5 d
immunoreactivity in L4-5 dorsal horn in (A) vehicle + saline, (C) STZ + saline
injection. Panels (B), (D), (F) and (H) are higher magnification of boxed are
applies to (C), (E) and (G) and the scale bar in (B) is 12.5 μm and applies t
dorsal horn at 6 weeks after STZ injection. Ratio of NET-immunoreactive pix
Methods). Four to twelve dorsal horn samples were used for evaluating av
experimental group are shown. *P < 0.05 (Mann–Whitney U-test) between
(Mann–Whitney U-test) between saline-treated and DSP-4-treated groups inEffects of STZ and DSP-4 on NET-immunoreactivity in the
lumbar spinal dorsal horn
The NA released from noradrenergic terminals was re-
uptaken by these terminals and reused. Therefore, the
extracellular and intracellular concentrations of NA de-
pend on the activity of this re-uptake. NA is mostly re-
uptaken by the Na+/Cl--dependent norepinephrine trans-
porter (NET). The genetic ablation of NETs results in an
increased extracellular NA level and decreased intracellu-
lar storage of NA [35], which indicates that the intra- andorsal horn. Representative photomicrographs of NET-
, (E) vehicle + DSP-4 and (G) STZ + DSP-4 rats at 6 weeks after STZ
a in (A), (C), (E) and (G), respectively. The scale bar in (A) is 50 μm and
o (D), (F) and (H). (I) Quantification of NET-immunoreactivity in L4-5
els to the total pixel number in the dorsal horn gray matter (see
erage ratio values in each rat. The mean ± SEM values of 4 rats for each
vehicle (Veh) and STZ groups in saline-treated animals; #P < 0.05
both STZ and Veh groups; NS, not significantly different.
Figure 6 Effects of STZ and DSP-4 on NA and 5-HT content in
the lumbar spinal cord. NA (A) and 5-HT (B) content in the
lumbar spinal cord at 6 weeks after STZ injection. The mean ± SEM
values of 5 rats for each experimental group are shown. The
samples were collected from the rats after behavior evaluation
(see Methods). *P < 0.05 (Kruskal-Wallis one-way ANOVA) between
saline-treated vehicle (Veh) + DW and STZ + DW groups; #P < 0.05;
##P < 0.01 (Mann–Whitney U-test) between saline-treated and
DSP-4-treated groups; NS, not significantly different.
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tivity of NETs. We therefore analyzed the expression of
NETs by immunohistochemistry in the lumbar spinal dor-
sal horn of rats treated with STZ and DSP-4. In rats treated
with either STZ or vehicle, NET-immunoreactivity was dis-
tributed throughout the dorsal laminae (Figure 5A-D). The
quantitative comparison of the pixel density indicated
that the fraction of NET-positive pixels was signifi-
cantly increased in the dorsal horn of STZ-treated rats
(Figure 5C-D, I). DSP-4 drastically eliminated the
NET-immunoreactivity in the dorsal horn both in the
STZ- and vehicle-treated rats (Figure 5E-I). After DSP-
4 treatment, there was no significant difference in the
ratio of NET-positive pixels between STZ- and vehicle-
treated rats (Figure 5I). These results indicated that
STZ increased the expression of NETs on the fibers in
the lumbar spinal dorsal horn.
Effects of STZ and DSP-4 on NA content in the lumbar
spinal cord
The increase in DBH- and NET-positive fibers in the
lumbar spinal dorsal horn would result in increased NA
production and re-uptake into the terminals. To directly
confirm this action, we measured the NA content in the
lumbar spinal cord tissues from the rats treated with
STZ, DSP-4 and DLX using high-performance liquid
chromatography (HPLC). We also measured the content
of 5-HT using the same homogenized samples that were
used for the NA content measurement. STZ significantly
increased NA content in the lumbar spinal cord (Figure 6A,
“Saline”). DLX did not significantly affect the NA content
(Figure 6A, “Saline”). DSP-4 significantly reduced the
spinal NA content in rats treated with STZ and vehicle
(Figure 6A, “DSP-4”). There was no significant difference in
NA content between STZ- and vehicle-treated rats as well
as between DLX- and distilled water (DW)-treated rats in
the lumbar spinal cord sampled after DSP-4-treatment.
Despite slight and insignificant increase in the spinal 5-HT
levels in STZ-treated animals, the 5-HT content was
not significantly affected by STZ and DSP-4 treat-
ments and was also insensitive to DLX (Figure 6B)
unlike the STZ- and DSP-4-induced changes in NA
levels (Figure 6A).
Discussion
Using DSP-4-induced selective ablation of the noradren-
ergic fibers, we demonstrate that the analgesic effect of
DLX in the STZ-induced PDN depends crucially on the
presence of intact noradrenergic fibers. Because our ana-
lyses indicated drastic changes in the amount of DBH-
and NET-expressing fibers in the dorsal horn and the
spinal content of NA in the STZ-treated animals, it is
highly likely that the potent anti-nociceptive effect of
DLX in the STZ-treated animals is mediated by the
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errant regulation of spinal NA systems. The mechanisms
underlying these effects are discussed below.
The analgesic effect of DLX depends on an intact NA system
DLX is an SNRI that shows inhibitory potency to NA
transporters and 5-HT transporters [36]. The present re-
sults support the finding that the analgesic effect of DLX
is mediated by its effect on NA transport because the sup-
pression of the DLX effect by DSP-4 pretreatment was
clearly observed when DSP-4 treatment was combined
with injection of an SSRI (fluoxetine) [28] (see Results).
This conclusion that the presence of serotoninergic fibers
is not sufficient to produce the anti-nociceptive effect of
DLX in PDN is also supported by a recent finding in STZ-
treated rats, that the anti-nociceptive effect of another
SNRI, venlafaxine, was completely abolished by yohimbine
pre-treatment but was only partially inhibited by pretreat-
ment with p-choloroamphetamine, an agent that dege-
nerates serotoninergic fibers [16]. However, partial but
significant reduction of analgesic effect of DLX and an-
other SNRI, milnacipran, by 5-HT receptor antagonists
has been described in STZ-treated PDN [12] and postop-
erative pain [37] models of rats. A possible interpretation
for these results is that activation of 5-HT receptors might
affect extracellular NA concentration, such as through
modulating NA release, and that the final common medi-
ator that regulate spinal nociceptive network is the NA
system, to which the 5-HT system lies upstream. This is a
possibility that might explain why manipulations of either
5-HT or NA system affect the effect of SNRI and elimina-
ting only the NA fibers could completely abolish its anal-
gesic effect, as evidenced in this study. Such a primary
role of the NA system in the anti-nociceptive effect of
SNRI is also supported by observations in other types of
chronic pain models in mice that genetically lack central
serotoninergic neurons [38]. In these mice, DLX exerted
marked analgesic effects in carrageenan- and formalin-
induced pain models to a similar degree as those observed
in the wild-type mice, again indicating a secondary in-
volvement of 5-HT system in the analgesic effect of DLX.
Altogether, in the chronic model of PDN as used in this
study and in other types of chronic pain models, the anal-
gesic effect of DLX requires intact NA systems that are
capable of releasing NA from nerve terminals.
Impaired NA homeostasis would underlie exaggerated
nociception in the STZ-diabetic model
This specific modulation of the NA system in the analgesic
effect of DLX in STZ-treated rats supports the notion that
STZ administration induces long-lasting aberrant modifi-
cation of the NA systems, which leads to pro-nociception.
NA is one of the principal mediators of endogenous ana-
lgesic mechanisms in the descending pain modulatorysystem in the spinal dorsal horn [26,27]. The elimination of
NA alone by genetic ablation of DBH or DSP-4 administra-
tion potently decreases the nociceptive threshold in mice
[39] and rats [32,33], as confirmed in this study. Conversely,
intrathecal NA administration increases tail-flick latency in
normal mice [40] and rats [41]. Additionally, DSP-4 admin-
istration, which drastically increased nociception sensitivity
in non-STZ-treated rats, did not further affect the lowered
nociceptive threshold in STZ-treated animals in this study
(Figure 2). This result is a reminiscence of the absence of
otherwise pro-nociceptive effect of 6-hydroxydopamine, an
NA synthesis neurotoxin, in STZ-treated mice with low-
ered nociception threshold [42]. These findings suggest that
specific defects in the regulation of NA homeostasis in the
spinal cord may underlie the pro-nociception in PDN. In
support of this interpretation, the effect of intrathecal NA
administration in elevating the nociceptive threshold was
markedly more potent in STZ-treated mice than in non-
diabetic mice [42]. An increase in the extracellular NA level
with DLX would be anticipated because it has been shown,
albeit not in a diabetic model, that intravenous injection of
milnacipran, which is an SNRI, increases extracellular NA
levels in the spinal dorsal horn as measured by microdialy-
sis in anesthetized mice with spinal nerve ligation-induced
neuropathy [43]. It is therefore speculated that STZ treat-
ment decreases the spinal NA level, which leads to exagger-
ated nociception.
Nevertheless, contrary to this speculation, the NA con-
tent in the spinal cord was significantly increased in STZ-
treated rats in the present study. This result was, however,
not unexpected because such an increase in NA in STZ-
treated rats is consistent with previous reports [44,45]. In
addition to this increase in NA level, the quantities of
DBH- and NET-expressing fibers in the dorsal horn were
significantly increased in STZ-treated rats. Because these
immunopositive fibers in the dorsal horn are drastically
abolished after DSP-4 treatment, these molecules are in-
deed expressed on the segmental branches of the descend-
ing noradrenergic fibers.
The NET in the central nervous system is primarily lo-
cated on the presynaptic membrane of noradrenergic
neurons and plays an essential role in the re-uptake of
extracellular NA from synaptic clefts to terminals
[46,47]. Recently, accumulated lines of evidence point to
a clear role of insulin in the regulation of NET expres-
sion and membrane localization. The NA uptake in
whole brain neuronal culture is inhibited by insulin [48].
The NET mRNA level in the locus coeruleus is reduced
by insulin [49] and elevated by STZ treatment [50]. Sur-
face expression of functional NETs in the hippocampal
neurons is increased in STZ-treated mice, and con-
versely, NETs are internalized by acute insulin adminis-
tration through phosphorylation of Ser/Thr kinase Akt/
PKB (protein kinase B) pathways [24].
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to distinguish between surface and internalized NET
molecules. However, it is expected that together with the
observations of these previous reports, the increased ex-
pression of NETs on the fibers in the dorsal horn due to
sustained hypoinsulinemia would result in an increased
amount of NETs localized on the membrane surface.
This activity would lead to an exaggerated NA uptake by
the terminals, which leads to decreased extrasynaptic or
intracleft NA concentration. Consequently, this decrease
in extracellular NA would directly lead to aberrant pro-
nociception. The genetic ablation of NETs, which de-
creases NA content in the spinal cord [51], produces
profound hypoalgesia [52]. This insulin-dependent NET
expression and the NA dependency of the spinal noci-
ceptive system support the recent view that hypoinsuli-
nemia itself, rather than hyperglycemia, would play a
larger role in the establishment of hyperalgesia [53]. In-
deed, insulin, at a dose not affecting the hyperglycemia,
has been shown to improve neuropathy and relief hyper-
algesia [22,25]. Because the NET is the primary target
molecule of DLX [54] for its primary effect on NA re-
uptake inhibition, the potent anti-nociceptive effect of
DLX in STZ-treated rats is, for the most part, attributed
to the direct inhibition of exaggerated NA transport in
the spinal cord.
Another possibility, which is not incompatible with the
interpretation described above, is that the release of NA is
lowered in STZ-treated rats. Bitar et al. described a signifi-
cant reduction in the ratio of 3-methoxy-4-hyroxyphenyl-
glycol (MHPG) to NA in the lumber spinal cord of the rat
at 30 days after STZ treatment and suggested a decreased
release or turnover of NA in this model [55]. This inter-
pretation is also compatible with the present result of in-
creased NA content in the lumber spinal cord. Decreased
NA release would result from decreased firing rate of
locus coeruleus neurons and release probability at the
spinal noradrenergic axon terminals in STZ-treated rats,
possibilities being required to be examined in the future
studies.
To date, the molecular mechanisms underlying the in-
crease in the expression of DBH in STZ-treated rats have
not been established. The involvement of the CREB path-
way in the regulation of tyrosine hydroxylase (TH) [56]
and TH expression in STZ-treated diabetic models [45]
has been documented. Though it has been shown that in-
crease in brain-derived neurotrophic factor (BDNF) fol-
lowing spinal nerve injury results in sprouting of DBH-
expressing fibers in the spinal cord [57], this mechanism
is unlikely to primarily underlie the increase in DBH-
positive fibers observed in the present study, because the
BDNF content in the spinal cord is not significantly af-
fected in a similar PDN model with STZ [58]. In addition
to these changes in NA synthesis, the changes in thesynaptic expression level of adrenoceptors [55,59] and
agonist potency [55,59,60] might also underlie the aber-
rant NA homeostasis in STZ-treated animals. Whatever
the mechanism, increased NA synthesis and storage in the
spinal cord in STZ models might result in a larger quantity
of NA in the tissue, as evaluated using HPLC (Figure 6).
Such augmented NA synthesis and storage would provide
support for the effective increase in extracellular NA levels
after NET blockade by DLX.
Mechanisms of anti-nociceptive effect of DLX
We failed to detect a significant increase in lumbar NA
level after DLX injection using HPLC analysis (Figure 6)
unlike previous studies that demonstrated a significant in-
crease in extracellular NA level induced by DLX in the rat
frontal cortex using microdialysis [61,62]. As the expres-
sion levels of DBH and the NET were increased in the
STZ-treated rats, it is speculated that the changes in
extracellular concentration of NA induced by DLX are
small compared to the large amount of intracellular stored
NA, which obscures the measurement using HPLC. The
microdialysis measurement in the dorsal horn in the non-
anesthetized animal is a challenging procedure that would
provide direct insight into the spinal mechanism of DLX
in future studies.
The present results do not necessarily rule out involve-
ment of changes in NA levels in supraspinal structures,
such as the limbic system, a pivotal target of nociceptive
signals in the brain [63] as well as a site underlying de-
pressive affection. The synaptic transmission of the amyg-
dala neurons, which shows robust synaptic potentiation in
chronic neuropathic pain models [64] including STZ-
models [65], is modulated by NA [66]. Additionally, the
changes in the activities in the amygdala neurons by
alpha-2 adrenoceptor agonists affect spinal nocifensive be-
haviors [67]. These observations might imply that the
changes in the amygdala activity by DLX might also
underlie these nociceptive effects. Further understanding
of the specific molecular facets of supraspinal and spinal
NA homeostasis will contribute toward the development
of medications with more specific pain-relieving effects in
patients with DM.
Clinically, DLX improves pain severity both in type 1
and 2 DM [68]. The PDN model used in this study with
STZ treatment mimics the type 1 DM with strong hypoin-
sulinemia. However, the present finding of the exacerbated
spinal nociception through impaired insulin-mediated
NA homeostasis might also be of importance in the type
2 DM, in which a larger portion of patients suffer the
neuropathic pain [3]. In the animal models for type 2
DM (ob/ob and db/db mice), it has been shown that,
despite increased insulin levels, the phosphorylation of
Akt is significantly reduced [69]. It is thus expected that
such impaired insulin/Akt signal-mediated NA homeostasis
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which would also be an important target of DLX for its an-
algesic effect.
We conclude that improvement of extracellular NA
homeostasis by inhibiting NETs is the primary mechan-
ism of the anti-nociceptive effect of DLX, which be-
comes highly potent in painful pathological states that
accompany the aberrant increase in NA synthesis and
re-uptake in PDN.
Conclusions
Impairment of the NA-mediated regulation of the spinal
nociceptive network would induce exaggerated nocicep-
tion in PDN. The mechanism may involve a reduced
amount of extracellular NA in the spinal cord due to ex-
aggerated NA uptake by overexpressed NETs. The se-
lective enhancement of reduced noradrenergic signals in
the spinal cord by inhibiting NA re-uptake might under-
lie the analgesic effect of DLX in a manner that is
dependent on descending NET-expressing noradrenergic
fibers which remain intact in PDN.
Methods
Preparation of the STZ-induced diabetic model
The manipulation of the animals conformed to the
Guiding Principles for the Care and Use of Animals in
the Field of Physiological Sciences of the Physiological
Society of Japan (1988). The study was approved by the
Animal Care Committee of The Jikei University School
of Medicine, Tokyo, Japan. Male Wistar rats, weighing
200–230 g, were rendered diabetic by an injection of
STZ (50 mg/kg, i.v.) (Sigma-Aldrich, Tokyo, Japan) dis-
solved in 0.9% sterile saline under deep anesthesia with
isoflurane. Age-matched control rats received equal vol-
umes of the vehicle (non-diabetic rats). The animals
fasted from the evening prior to the day of STZ admin-
istration; they were allowed to feed again after adminis-
tration of the agent. Diabetes was confirmed one week
after injection of STZ by measuring glucose blood levels
in samples taken from the tail vein using a OneTouch
Ultra blood glucose meter (Johnson & Johnson, Tokyo,
Japan). Because 600 mg/dl was the detection limit of the
blood glucose meter, the blood glucose levels over
600 mg/dl were defined as 600 mg/dl.
von Frey filament test
To assess mechanical allodynia, we determined the
withdrawal threshold of hind paws to mechanical stimu-
lation using a series of von Frey filaments (North Coast
Medical, Inc., Gilroy, CA, USA). We used eight different
von Frey filaments ranging from 0.4 g to 15 g. The rats
were placed on a metal mesh floor and von Frey filaments
were applied from underneath the floor. We estimated the
paw withdrawal thresholds by the up-and-down method[70]; we used the mean of right and left paw responses for
each rat.
Hargreaves test
We determined the latency of the hindpaw withdrawal
evoked by thermal stimulation using a modified Har-
greaves Box (University of California, San Diego, CA,
USA) [71]. The rats were placed on a glass floor main-
tained at 30°C in a clear plastic chamber. We focused a
mobile radiant heat source, which was located under the
glass floor, onto the plantar surface of the right and left
hindpaw. We measured paw withdrawal latencies twice
for each hindpaw, and we used the mean of the four
values for analysis. Five min of rest was allowed between
trials. To prevent tissue damage, we set an automatic
cutoff at 20 s.
Lesions of the noradrenergic system
To induce lesions in the noradrenergic system, we used
DSP-4 (Sigma-Aldrich, Tokyo, Japan), which is a select-
ive neurotoxin that preferentially degenerates noradren-
ergic axons originated from the locus coeruleus [72].
Four weeks after STZ or vehicle injection, the rats received
an injection of DSP-4 (50 mg/kg, i.p.) dissolved in 0.9%
sterile saline [32] under deep anesthesia with isoflurane.
The control rats received equal volumes of saline rather
than DSP-4. In a subgroup of STZ rats that received DSP-4,
fluoxetine (10 mg/kg, i.p.) (Sigma-Aldrich, Tokyo, Japan),
which is a selective 5-HT uptake inhibitor, was administered
30 min before the DSP-4 injection to assess the likely
involvement of the effect of DSP-4 on serotoninergic
terminals [28]. The control rats received equal volumes of
saline rather than fluoxetine.
Administration of DLX
Six weeks after STZ or vehicle injection, the rats re-
ceived i.p. injection of DLX (10 mg/kg with of 1% DW
solution) (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA) under deep anesthesia with isoflurane. The
control rats received equal volumes of DW.
Experimental protocols
The von Frey filament and the Hargreaves tests were
performed 1 day before the injection of STZ (n = 30 rats)
or vehicle (n = 20) immediately before the 1-day fasting.
These tests were performed every week until the 6th
week after STZ or vehicle injection. On the 28th day
after STZ-treatment (4th week), these tests were performed
60 min before the injection of 1) DSP-4 (n = 10 rats) or 2)
saline (n = 10) in STZ-treated or vehicle-treated rats and 3)
DSP-4 + fluoxetine (n = 5) or 4) DSP-4 + saline (n = 5) in
STZ-treated rats. On the 42nd day after STZ-treatment
(6th week), at which time DLX (n = 5 rats) or DW (n = 5)
was injected, thermal hyperalgesia was assessed twice at
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allodynia was assessed at 30 min before and 90 min
after the injection. The values obtained before and
after the injection were termed “pre-DLX” and “post-DLX,”
respectively, and the value of “post-DLX” divided by
“pre-DLX” was considered to be a measurement for
the effect of DLX in these tests. The behavior assessment
was made by an experimenter who was blinded to the
medication application.
Measurements of NA and 5-HT
Two hours after the injection of DLX or DW, the rats
were sacrificed under deep anesthesia with isoflurane. The
lumbar spinal cord was dissected, weighed, immediately
frozen in liquid nitrogen and subsequently kept at −80°C.
Each lumbar spinal cord was homogenized in 200 μl of
0.2 M perchloric acid containing 100 μM Na2-EDTA as
an internal standard, and centrifuged at 20000 × g at 4°C
for 15 min. The supernatants were filtered through a 0.2-
μm syringe filter and subsequently kept at pH 3.0 by add-
ing 1 M sodium acetate. The concentration of NA and 5-
HT was measured using reverse-phase HPLC with elec-
trochemical detection (SRL, Inc., Tokyo, Japan).
Confocal microscopic fluorescence immunohistochemistry
For immunohistochemistry, eight STZ (four DSP-4-
treated and four saline-treated) and eight vehicle (four
DSP-4-treated and four saline-treated) rats at the 6th week
after STZ or vehicle injection were anesthetized with so-
dium pentobarbital (50 mg/kg) and were intracardially
perfused with cold phosphate-buffered saline (PBS) subse-
quently with 4% paraformaldehyde (PFA) in 0.1 M phos-
phate buffer (pH 7.4). The lumbar (L4–L5) spinal cord
segments were removed and post-fixed in 4% PFA over-
night at 4°C. After cryoprotection through a graded series
of sucrose replacements (10%, 20%, and 30% in PBS) at
4°C, each segment was embedded in OCT Compound
(4583, Sakura Finetek, Tokyo, Japan) and stored at −80°C.
The spinal cord segments were cut transversely on a
cryostat (CM1850, Leica Biosystems, Tokyo, Japan) into
30-μm-thick sections. The sections were mounted on sil-
iconized slides for immunostaining. Nonspecific labeling
was blocked by incubation in 1% normal goat serum and
0.4% Triton X-100 in PBS. After blocking, the sections
were incubated overnight at 4°C in the mouse monoclo-
nal antibody to DBH (1:600, EMD Millipore, Billerica,
MA, USA) or the NET (1:500, Mab Technologies, Stone
Mountain, GA, USA) diluted in blocking solution.
After incubation in the primary antibody cocktail, the
sections were rinsed in PBS and incubated in a cocktail
of goat anti-mouse Alexa Fluor 488 labeled secondary
antibodies (1:400, Invitrogen, Grand Island, NY, USA)
for 1 hour at room temperature. The sections were sub-
sequently rinsed in PBS and mounted with Aqua-Poly/Mount (Polysciences, Inc., Warrington, PA, USA). The
sections were examined using a confocal microscope
(Fluoview FV300, Olympus Corporation, Tokyo, Japan).
The control sections were processed with the primary
antibody omitted from the primary antibody cocktail; in
all cases, only the labeling with the secondary fluores-
cent antibodies corresponding to the non-omitted pri-
mary antibody was observed.
Quantification of DBH- and NET-positive fibers in the
lumbar spinal dorsal horn
The areas of the DBH- and NET-immunoreactive pixels
in projection confocal images were calculated by fluores-
cence thresholding with maximum entropy method
(NIH ImageJ; Bethesda, MD, USA) and normalized by
the area of the dorsal horn gray matter (either side of
transverse sections dorsal to the ventromost edge of the
white matter at the midline). Each projection confocal
image was created using 16 optical sections with a 2.8-
μm interval (10× objective; 1024 × 1024 pixels) and 18
sections with a 1.4-μm interval (20× objective; 1024 ×
1024 pixels) for DBH and NET, respectively. After the
primary measurement by an author, other authors who
were blinded to the medication treatments re-examined
the confocal images and results of the evaluation in a
blinded manner.
Data and statistical analysis
Values are expressed as the mean values ± standard error
of the mean (SEM). The statistical comparisons were
made using one-way analysis of variance (ANOVA) for
repeated-measures followed by Bonferroni post hoc test
for multiple comparisons of the time course, Wilcoxon
signed-rank test for between pre-DLX and post-DLX
comparisons, Kruskal-Wallis one-way ANOVA for the
inter-group multiple comparisons and Mann–Whitney
U-test for other comparisons between two groups. Dif-
ferences with a probability (P) less than 0.05 were con-
sidered to be statistically significant.
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